Literature DB >> 16209875

Virus free, cell-based assay for the quantification of murine type I interferons.

Mariela Bollati-Fogolín1, Werner Müller.   

Abstract

Interferons (IFNs) are potent biologically active proteins synthesized and secreted by somatic cells of all mammalian species. They have been well characterized, with respect to structure, biological activities and clinical therapeutic effects. Historically, IFN antiviral activity assays were the first type of bioassays developed to measure the relative activity or potency of IFN preparations. Here we report a new virus free, cell-based assay to quantify murine type I IFN. It basically consists of an indicator cell line in which the Cre-recombinase is driven by the IFN-inducible Mx1 promoter and, when activated, deletes a stop cassette upstream of the eGFP coding region, resulting in the expression of eGFP. The percentage of eGFP expressing cells accurately correlates to the amount of type I IFN added to the culture and can easily be monitored.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16209875     DOI: 10.1016/j.jim.2005.08.005

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model.

Authors:  Fernando S F Guimarães; Lucas F Andrade; Sharon T Martins; Ana P R Abud; Reginaldo V Sene; Carla Wanderer; Inés Tiscornia; Mariela Bollati-Fogolín; Dorly F Buchi; Edvaldo S Trindade
Journal:  BMC Cancer       Date:  2010-03-25       Impact factor: 4.430

2.  Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes.

Authors:  Wibke Bayer; Ruth Lietz; Teona Ontikatze; Lena Johrden; Matthias Tenbusch; Ghulam Nabi; Simone Schimmer; Peter Groitl; Hans Wolf; Cassandra M Berry; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  Retrovirology       Date:  2011-09-26       Impact factor: 4.602

3.  Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis.

Authors:  Zhijian Yu; Zhen Huang; Chongwen Shao; Yuanjian Huang; Fan Zhang; Jin Yang; Lili Deng; Zhongming Zeng; Qiwen Deng; Weiseng Zeng
Journal:  Virol J       Date:  2011-12-08       Impact factor: 4.099

4.  Different antiviral effects of IFNα subtypes in a mouse model of HBV infection.

Authors:  Jingjiao Song; Sheng Li; Yun Zhou; Jia Liu; Sandra Francois; Mengji Lu; Dongliang Yang; Ulf Dittmer; Kathrin Sutter
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

5.  Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8+ T Cell Responses.

Authors:  Julia Dickow; Sandra Francois; Rouven-Luca Kaiserling; Anna Malyshkina; Ingo Drexler; Astrid Maria Westendorf; Karl Sebastian Lang; Mario L Santiago; Ulf Dittmer; Kathrin Sutter
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

6.  Immunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection.

Authors:  Mara Schwerdtfeger; Julia Dickow; Yasmin Schmitz; Sandra Francois; Zehra Karakoese; Anna Malyshkina; Torben Knuschke; Ulf Dittmer; Kathrin Sutter
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

7.  Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection.

Authors:  Kathrin Gibbert; Jara J Joedicke; Andreas Meryk; Mirko Trilling; Sandra Francois; Janine Duppach; Anke Kraft; Karl S Lang; Ulf Dittmer
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

8.  Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine.

Authors:  Dennis Lapuente; Viktoria Stab; Michael Storcksdieck Genannt Bonsmann; Andre Maaske; Mario Köster; Han Xiao; Christina Ehrhardt; Matthias Tenbusch
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.